Searle DayPro
Executive Summary
Pediatric study submitted to extend exclusivity of oxaprozin. FDA will review the trial to determine if it meets the criteria for a six-month extension of exclusivity under the FDA Modernization Act. The product's exclusivity was set to expire Oct. 29